UBI (31-38)
UBI (31-38) is a Ubiquicidin-derived octapeptide and anti-bacterial agent. UBI (31-38) selectively interacts with anionic phospholipid membranes and restricts lipid lateral motion. UBI (31-38) induces anionic vesicle aggregation via electrostatic repulsion screening, and undergoes conformational changes in membrane-mimicking environments. UBI (31-38) can be used for the research of infection imaging probes.
For research use only. We do not sell to patients.
- CAS No.: 290360-66-6
- Formula: C46H81N19O11S
- Molecular Weight:1108.32
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
In Vitro
UBI (31-38) undergoes a random coil-to-structural transition in TFE-containing buffer and in an anionic model bacterial membrane[1].
UBI (31-38) selectively binds to anionic model bacterial membranes (POPG LUVs) with an association constant of 2.58 × 105/M, while showing no significant interaction with zwitterionic model mammalian membranes (POPC LUVs)[1].
UBI (31-38) (2 h) uptake by Staphylococcus aureus ATCC 25923 is driven by electrostatic interactions[1].
UBI (31-38) induces aggregation of anionic model bacterial membranes (POPG LUVs) at peptide-to-lipid molar ratios of 10% and above, with significant aggregation occurring at 40% P/L, while having no effect on zwitterionic model mammalian membranes (POPC LUVs)[1].
UBI (31-38) (P/L = 4%) restricts the lateral motion of lipids in anionic model bacterial membranes (DPPG LUVs) at a peptide-to-lipid molar ratio of 4%, reducing the lateral diffusion coefficient by 28%, while leaving lipid internal motions unaffected[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS No. 290360-66-6
-
Molecular Weight 1108.32
-
Formula C46H81N19O11S
-
Sequence
Arg-Ala-Lys-Arg-Arg-Met-Gln-Tyr
-
Sequence Shortening
RAKRRMQY
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
UBI (31-38) Related Classifications
HY-P11430 Related Classifications
Powered by Bioz
Keywords